Research and Markets (http://www.researchandmarkets.com/research/1c756d/rheumatoid_arthrit)
has announced the addition of Frost & Sullivan's new report "Rheumatoid
Arthritis Therapeutics Market in Thailand" to their offering.
This Frost & Sullivan research service titled Rheumatoid
Arthritis Therapeutics Market in Thailand provides competitive
structure, market analysis, and future trends. In this research, Frost &
Sullivan's expert analysts thoroughly examine the following markets:
disease-modifying antirheumatic drugs (DMARDs), nonsteroidal
anti-inflammatory drugs (NSAIDs), and biologics.
DMARDS and Biologics Find Increased Application in the Treatment of
Rheumatoid Arthritis in Asia Pacific
While DMARDs status as the treatment of choice for rheumatoid arthritis
(RA) is intact, biologics is emerging as a viable treatment option for
more severe cases, and it is the focus of pharmaceutical companies
clinical research. However, with high costs offsetting their outstanding
efficacy, especially in developing markets, the market is open to for
generic DMARDs. DMARDs affordability makes them the preferred mode of RA
treatment where the costs are either reimbursed by governments or borne
by the patients. The availability of generic DMARDs, coupled with their
relative efficacy and low cost allows clinicians to prescribe DMARD
therapies singly or in combination with other non-biological DMARDs,
says the analyst of this research.
DMARDs cost-effectiveness is expected to go a long way in winning them a
spot on the reimbursement lists, as governments are looking to curtail
spiraling healthcare costs. Countries such as South Korea, Malaysia, and
Taiwan that have comprehensive healthcare tend to promote generics and
low-cost therapies, although the newer and more expensive options may be
more effective. Moreover, patients are more willing to make
out-of-pocket payments for inexpensive DMARDs where reimbursement is not
available. DMARDs are expected to continue their market reign as usage
of NSAIDs declines and growth for biologics occurs gradually.
Nevertheless, their market penetration in Asia Pacific is not likely to
be homogeneous due to varying government regulations regarding approval
of drugs for treatment and reimbursement.
Establishing a footprint in markets that offer reimbursement is heavily
dependent on getting the therapies into the reimbursement lists. In
countries such as China, the Philippines, and India, which do not have
extensive government reimbursement, the affordability of drugs is
critical when patients have to make out-of-pocket payments. Market
participants could collaborate with governments to establish the
implications of the disease, in terms of potential disability and cost
burden, to highlight the need for early therapy. Pharmaceutical
companies could partner with governments and non-government bodies in
instituting awareness programs for the disease to enable patients to
seek medical attention sooner, notes the analyst. This could enhance the
quality of life for patients and reduce the overall cost of treatment in
the long term.
Market Sectors
Expert Frost & Sullivan analysts thoroughly examine the following market
sectors in this research: